British biologist
Gerard Ian Evan FRS , FMedSci (born 17 August 1955) is a British biologist and, since May 2022, Professor of Cancer Biology at King's College London and a principal group leader in the Francis Crick Institute. Prior to this he was Sir William Dunn Professor of Biochemistry and Head of Biochemistry at the University of Cambridge (2009-2022).[ 11] [ 13]
Education
Evan was educated at St Peter's College, Oxford, where he studied Biochemistry , and King's College, Cambridge , where he was awarded his PhD in 1982 for research using Monoclonal antibodies .[ 10] [ 14]
Research
Evan does research to the determine the molecular basis of cancer .[ 15] [ 16] [ 17] [ 18] [ 19] [ 20] [ 21] [ 22]
Career
Prior to Cambridge, Evan was Royal Society Napier Professor at University College London and the Imperial Cancer Research Fund (1988-99), then Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology, at University of California, San Francisco (1999-2011) .
References
^ http://www.acmedsci.ac.uk/p59fid5303.html [dead link ] ^ Finch, A. J.; Soucek, L.; Junttila, M. R.; Swigart, L. B.; Evan, G. I. (2009). "Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/ -Catenin Pathway Activation" . Molecular and Cellular Biology . 29 (19): 5306– 5315. doi :10.1128/MCB.01745-08 . PMC 2747972 PMID 19635809 . ^ Garcia, D.; Warr, M. R.; Martins, C. P.; Brown Swigart, L.; Passegue, E.; Evan, G. I. (2011). "Validation of MdmX as a therapeutic target for reactivating p53 in tumors" . Genes & Development . 25 (16): 1746– 1757. doi :10.1101/gad.16722111 . PMC 3165938 PMID 21852537 . ^ Murphy, D. J.; Junttila, M. R.; Pouyet, L.; Karnezis, A.; Shchors, K.; Bui, D. A.; Brown-Swigart, L.; Johnson, L.; Evan, G. I. (2008). "Distinct Thresholds Govern Myc's Biological Output in Vivo" . Cancer Cell . 14 (6): 447– 457. doi :10.1016/j.ccr.2008.10.018 . PMC 2723751 PMID 19061836 . ^ Sodir, N. M.; Swigart, L. B.; Karnezis, A. N.; Hanahan, D.; Evan, G. I.; Soucek, L. (2011). "Endogenous Myc maintains the tumor microenvironment" . Genes & Development . 25 (9): 907– 916. doi :10.1101/gad.2038411 . PMC 3084025 PMID 21478273 . ^ Kain, K. (2008). "The future of cancer therapy: An interview with Gerard Evan" . Disease Models and Mechanisms . 1 (2– 3): 90– 93. doi :10.1242/dmm.001396 . PMC 2562192 PMID 19048069 . ^ Anon (2008). "Making the paper: Gerard Evan" . Nature . 455 (7213): xiii. doi :10.1038/7213xiiia S2CID 4410691 . ^ Evan, G. (2012). "Taking a Back Door to Target Myc". Science . 335 (6066): 293– 294. Bibcode :2012Sci...335..293E . doi :10.1126/science.1217819 . PMID 22267799 . S2CID 26445434 . ^ Junttila, Melissa R.; Evan, Gerard I. (2009). "P53 — a Jack of all trades but master of none". Nature Reviews Cancer . 9 (11): 821– 829. doi :10.1038/nrc2728 . PMID 19776747 . S2CID 29250930 . ^ a b c d "EVAN, Prof. Gerard Ian" . Who's Who 2013, A & C Black, an imprint of Bloomsbury Publishing plc, 2013; online edn, Oxford University Press .(subscription required) ^ a b "UCSF Departments of Pathology and Laboratory Medicine | About | Faculty | Gerard I. Evan, PhD, FRS, FMedSci" . Archived from the original on 1 June 2013.^ "Gerard Evan : Cancer Research UK" . Archived from the original on 10 March 2014.^ Gerard Evan publications indexed by Microsoft Academic ^ Evan, Gerard (1982). Monoclonal antibodies as reagents for the analysis of cell surfaces ^ Christophorou, M. A.; Ringshausen, I.; Finch, A. J.; Swigart, L. B.; Evan, G. I. (2006). "The pathological response to DNA damage does not contribute to p53-mediated tumour suppression". Nature . 443 (7108): 214– 217. Bibcode :2006Natur.443..214C . doi :10.1038/nature05077 . PMID 16957739 . S2CID 4417336 . ^ Junttila, M. R.; Karnezis, A. N.; Garcia, D.; Madriles, F.; Kortlever, R. M.; Rostker, F.; Brown Swigart, L.; Pham, D. M.; Seo, Y.; Evan, G. I.; Martins, C. P. (2010). "Selective activation of p53-mediated tumour suppression in high-grade tumours" . Nature . 468 (7323): 567– 571. Bibcode :2010Natur.468..567J . doi :10.1038/nature09526 . PMC 3011233 PMID 21107427 . ^ Soucek, L. ; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. (2008). "Modelling Myc inhibition as a cancer therapy" . Nature . 455 (7213): 679– 683. Bibcode :2008Natur.455..679S . doi :10.1038/nature07260 . PMC 4485609 PMID 18716624 .^ Evan, Gerard I. ; Vousden, Karen H. (2001). "Proliferation, cell cycle and apoptosis in cancer". Nature . 411 (6835): 342– 348. Bibcode :2001Natur.411..342E . doi :10.1038/35077213 . PMID 11357141 . S2CID 4414024 .^ Hueber, A. O.; Zörnig, M.; Lyon, D.; Suda, T.; Nagata, S.; Evan, G. I. (1997). "Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis". Science . 278 (5341): 1305– 1309. Bibcode :1997Sci...278.1305H . doi :10.1126/science.278.5341.1305 . PMID 9360929 . ^ Chittenden, T.; Harrington, E. A.; O'Connor, R.; Remington, C.; Lutz, R. J.; Evan, G. I.; Guild, B. C. (1995). "Induction of apoptosis by the Bcl-2 homologue Bak". Nature . 374 (6524): 733– 736. Bibcode :1995Natur.374..733C . doi :10.1038/374733a0 . PMID 7715730 . S2CID 4315947 . ^ Fanidi, A.; Harrington, E. A.; Evan, G. I. (1992). "Cooperative interaction between c-myc and bcl-2 proto-oncogenes". Nature . 359 (6395): 554– 556. Bibcode :1992Natur.359..554F . doi :10.1038/359554a0 . PMID 1406976 . S2CID 4247014 . ^ Amati, B.; Dalton, S.; Brooks, M. W.; Littlewood, T. D.; Evan, G. I.; Land, H. (1992). "Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max". Nature . 359 (6394): 423– 426. Bibcode :1992Natur.359..423A . doi :10.1038/359423a0 . PMID 1406955 . S2CID 4362486 .
External links
